S3026
Invited Speaker
ESTRO 2026
only in guideline development but also in implementation support.
chemoradiotherapy will be discussed, including the view that this strategy will appear more promising in esophageal squamous cell carcinoma than in adenocarcinoma. Overall, the presentation will conclude that radiotherapy will be the central organ- preserving modality, but that safe adoption of organ preservation will depend on disease-specific evidence and careful multidisciplinary selection. 5398 The implementation of guidelines across the world: How should we act? Banu Atalar Radiation Oncology, Anadolu Medical Center Hospital, Istanbul, Turkey The implementation of guidelines across the world: How should we act? The implementation of clinical guidelines in radiation oncology represents a critical global challenge. Over the past decades, the oncology community has made substantial progress in generating high-quality evidence and developing comprehensive international guidelines through leading organizations such as the European Society for Radiotherapy and Oncology and the American Society of Clinical Oncology. Despite these advances, significant variability persists in the translation of evidence-based recommendations into routine clinical practice across different regions of the world. This presentation addresses the persistent gap between guideline development and real-world implementation. While scientific evidence is increasingly globalized, healthcare delivery remains inherently local, influenced by diverse resource availability, health system structures, and organizational cultures. Key barriers to implementation are multifactorial and include resource limitations such as infrastructure and workforce, health system constraints related to policy and reimbursement, and human factors including awareness, training, and resistance to change. Global disparities in radiotherapy access further complicate the implementation of standardized recommendations, particularly in low- and middle- income settings. In this context, the development and adoption of resource-adapted guidelines emerge as essential strategies to ensure feasibility while maintaining quality of care across heterogeneous healthcare environments. A multi-level implementation framework: spanning global, national, and institutional levels is proposed to enable more effective translation of guidelines into practice. This approach underscores the need for stronger engagement of international societies, not
Ultimately, the value of clinical guidelines lies not in their publication, but in their impact on patient outcomes. Bridging the gap between evidence and practice is therefore essential to achieving equitable, high-quality cancer care worldwide. References: Zubizarreta EH et al. The Lancet Oncology 2021 Santos PMG et al, Reda Journal 2025 5401 The future of education in radiation oncology Luca Boldrini Dipartimento di Diagnostica per Immagini e Radioterapia oncologica, Università Cattolica del Sacro Cuore, Rome, Italy This talk will explore the evolving landscape of education in radiation oncology, highlighting current challenges, emerging trends, and future directions to ensure a competent and sustainable workforce. Contemporary educational frameworks, including competency-based curricula, ESTRO initiatives, and diverse teaching formats such as online, hybrid, and
simulation-based learning will be reviewed. The current landscape indicates a shift from
knowledge-based to competency-based education, with increased adoption of formative assessments and digital learning. However, challenges persist, including workforce shortages, technological disparities, resistance to change, and the need for standardized global training. Future radiation oncology education should integrate competence, technology, compassion, global collaboration, and standardized curricula to enhance accessibility, equity, and lifelong learning, ultimately improving patient care outcomes. 5402 SABR for oligometastatic gynaecological cancers: Where do we stand? Gabriella Macchia, Francesco Deodato Radiation Oncology Unit, Responsible Research Hospital, Campobasso, Italy The concept of oligometastatic disease in gynecological cancers is transitioning from a paradigm driven by technical feasibility to one increasingly grounded in tumor biology. This shift is particularly relevant across cervical [1], endometrial [2], and ovarian [3, 4] cancers, where distinct biological behaviors challenge uniform treatment approaches and require refined patient selection.
Made with FlippingBook - Share PDF online